Appeal No. 2004-1040 Page 3
Application No. 09/770,643
The specification also discloses that “[a] polymorphism was identified that results
in a C-or-T transition at, for example, the position corresponding to nucleotide 812 of
SEQ ID NO:1 that can result in a ser or leu being present at, for example, amino acid
position 271 of SEQ ID NO:2.
“Neurexins have been associated with, inter alia, mediating neural processes,
seizures, signaling, exocytosis, cancer, and development. Neurexins can also serve as
receptors for latrotoxins.” Page 1. The specification does not disclose what role the
protein of SEQ ID NO:2 plays in any physiological process, but contemplates
“processes for identifying compounds that modulate, i.e., act as agonists or antagonists,
of NHP expression and/or NHP activity that utilize purified preparations of the described
NHPs and/or NHP product, or cells expressing the same. Such compounds can be
used as therapeutic agents for the treatment of a wide variety of symptoms associated
with biological disorders or imbalances.” Page 2.
The specification also discloses that “suitably labeled NHP nucleotide probes can
be used to screen a human genomic library using appropriately stringent conditions or
by PCR. The identification and characterization of human genomic clones is helpful for
identifying polymorphisms . . . , determining the genomic structure of a given
locus/allele, and designing diagnostic tests.” Page 10.
The specification discloses that “[t]he NHP proteins or peptides, NHP fusion
proteins, NHP nucleotide sequences, host cell expression systems, antibodies,
antagonists, agonists and genetically engineered cells and animals can be used for
screening for drugs . . . effective in the treatment of the symptomatic or phenotypic
manifestations of perturbing the normal function of NHP in the body.” Page 14. Or “the
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007